Information Provided By: 
Fly News Breaks for October 16, 2019
PFE
Oct 16, 2019 | 16:58 EDT
BofA/Merrill analyst Geoff Meacham reinstated coverage of Pfizer with a Neutral rating and $37 price target, saying that he believes the company's near-term pipeline is priced into shares and that he needs additional clarity on the pipeline.
News For PFE From the Last 2 Days
PFE
Apr 22, 2024 | 08:13 EDT
Pfizer announced that the European Commission, or EC, has granted marketing authorization for Emblaveo for the treatment of adult patients with complicated intra-abdominal infections, or cIAI, hospital-acquired pneumonia, or HAP, including ventilator-associated pneumonia, or VAP, and complicated urinary tract infections, or cUTI, including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
